TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12414853

Group type: EXPERIMENTAL
Intervention: Oral DHEA (50 mg/d)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional hormonal replacement therapy (HRT) (20 micro g ethinyl estradiol/0.1 mg levonorgestrel)
Number of subjects: 61
Study: 10334133

Group type: EXPERIMENTAL
Intervention: CDP + TBNA
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: TBNA alone
Number of subjects: 55

Group type: COMPARATOR
Intervention: CDP
Number of subjects: 55
Study: 8565604

Group type: EXPERIMENTAL
Intervention: 0.75 percent metronidazole gel applied twice daily to the right side of the face
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5 percent permethrin cream applied daily to the left side of the face
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.75 percent metronidazole gel
Number of subjects: 6

Group type: COMPARATOR
Intervention: 5 percent permethrin cream
Number of subjects: 6
Study: 31994767

Group type: EXPERIMENTAL
Intervention: Multidomain attention training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 78
Study: 30318741

Group type: EXPERIMENTAL
Intervention: 90-degree selective laser trabeculoplasty (SLT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 360-degree selective laser trabeculoplasty (SLT)
Number of subjects: 0
Study: 28161303

Group type: EXPERIMENTAL
Intervention: Exenatide (GLP-1 group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Acarbose (Control group)
Number of subjects: 36
Study: 25683227

Group type: EXPERIMENTAL
Intervention: AWARE (novel electronic medical record dashboard)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Existing EMR (control)
Number of subjects: 80
Study: 23392314

Group type: EXPERIMENTAL
Intervention: Modified 3-snip punctoplasty with self-retaining bicanaliculus stents (Group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard 3-snip punctoplasty (Group A)
Number of subjects: 32
Study: 21482950

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.5 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 17289660

Group type: EXPERIMENTAL
Intervention: Self-management course (n = 78)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (n = 102)
Number of subjects: 180
Study: 15644830

Group type: EXPERIMENTAL
Intervention: 0.5 mg Budesonide Inhalation Suspension (BIS)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 1.0 mg Budesonide Inhalation Suspension (BIS)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 12897288

Group type: EXPERIMENTAL
Intervention: Physician aware of rapid influenza test result
Number of subjects: 418

Group type: COMPARATOR
Intervention: Physician unaware of rapid influenza test result
Number of subjects: 418
Study: 11109684

Group type: EXPERIMENTAL
Intervention: Moderate intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 8853758

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 1513963

Group type: EXPERIMENTAL
Intervention: School-and-home condition (n = 45)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: School-only condition (n = 43)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control condition (n = 44)
Number of subjects: 132
Study: 6482417

Group type: EXPERIMENTAL
Intervention: Psychophysical transformations using synthesized /Cej/‐type utterances with different F2 and F3 onset frequencies
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Predictions of percent /r/ responses derived from regression analyses based on mel transformations and Bark transformations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Category boundaries estimation
Number of subjects: 8
Study: 30755464

Group type: EXPERIMENTAL
Intervention: Teen-tot services plus 5 interactive parenting and life skills modules delivered by a nurse and social worker over the infant's first 15 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Teen-tot services alone
Number of subjects: 140
Study: 29967649

Group type: EXPERIMENTAL
Intervention: Yoga intervention (8 weeks, twice weekly)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 27
Study: 27659507

Group type: EXPERIMENTAL
Intervention: Testing of sputum using Xpert MTB/RIF assay and urine using Determine TB-LAM and Xpert after urine concentration by centrifugation
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Testing of sputum using Xpert MTB/RIF assay (standard of care)
Number of subjects: 1300
Study: 24175912

Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLC) Program including diet (overweight: 1700 kcal/day, obese: 1800 kcal/day) and mild physical activity (30 min/day, 3 times/week)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLC) Program
Number of subjects: 61
Study: 21889306

Group type: EXPERIMENTAL
Intervention: DASS‐21 depression subscale
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: DASS‐21 anxiety subscale
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: DASS‐21 stress subscale
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: DASS‐21 aggregate score of 'negative affect'
Number of subjects: 154
Study: 20353105

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with active-blood and dissolve-stasis herbs and rehabilitation training (Group A)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with rehabilitation training (Group B)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Herbs combined with rehabilitation training (Group C)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Rehabilitation training alone (Group D)
Number of subjects: 320
Study: 18181732

Group type: EXPERIMENTAL
Intervention: Probiotics (specific strains not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG and Saccharomyces boulardii
Number of subjects: 0
Study: 15960409

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study: 14557456

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity measured with the euglycemic, hyperinsulinemic clamp
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Insulin secretion measured as the acute response to iv arginine (5 g)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Baseline IMT (0.81 ± 0.14 mm) and progression in IMT over 5 years
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Maximal IMT (1.42 ± 0.42 mm) at baseline
Number of subjects: 84
Study: 10851578

Group type: EXPERIMENTAL
Intervention: Fistulectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fistulotomy
Number of subjects: 40
Study: 8609098

Group type: EXPERIMENTAL
Intervention: Individualized asthma self-management
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group asthma self-management
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no self-management training)
Number of subjects: 34
Study: 1953004

Group type: EXPERIMENTAL
Intervention: Controlled release salbutamol (CRS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7458885

Group type: EXPERIMENTAL
Intervention: Amitriptyline or imipramine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 31781100

Group type: EXPERIMENTAL
Intervention: Vi-PS vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vi-TT vaccine
Number of subjects: 0
Study: 29722285

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.5 µg/kg/minute (Group R 0.5)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Remifentanil at 1.0 µg/kg/minute (Group R 1.0)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline infusion (Group S)
Number of subjects: 75
Study: 27454267

Group type: EXPERIMENTAL
Intervention: Percutaneous bipolar RF neurotomy on S2 and S3 nerves
Number of subjects: 10

Group type: COMPARATOR
Intervention: Optimized conventional treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Urodynamic study (UDS) parameters
Number of subjects: 10
Study: 23828194

Group type: EXPERIMENTAL
Intervention: Camera‐ and software‐based device (FACE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dye‐staining method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Visual‐tactile inspection
Number of subjects: 100
Study: 22801581

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 μg kg(‐1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 μg kg(‐1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Remifentanil 3 μg kg(‐1)
Number of subjects: 96
Study: 20934602

Group type: EXPERIMENTAL
Intervention: Preexercise supplement (Game Time; containing caffeine, creatine, and amino acids)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Preexercise supplement (Game Time)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 19017831

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Sustained-released nifedipine
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 3535
Study: 16539632

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Thymoglobulin
Number of subjects: 20
Study: 12721186

Group type: EXPERIMENTAL
Intervention: 5-day embryo culture
Number of subjects: 226

Group type: COMPARATOR
Intervention: 2-day embryo culture
Number of subjects: 226

Group type: COMPARATOR
Intervention: Arrested embryos transfer
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Blastocyst transfer on day 5
Number of subjects: 226
Study: 11232384

Group type: EXPERIMENTAL
Intervention: Systematic Clinical Demonstration Methodology (SCDM)
Number of subjects: 0
Study: 8549030

Group type: EXPERIMENTAL
Intervention: Netivudine 400 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Netivudine 800 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1677894

Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6838671

Group type: EXPERIMENTAL
Intervention: Experimental diet (specific popular diet free of additives, preservatives, fruit, red meat, herbs, and dairy products)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 26
Study: 31452928

Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg + methotrexate
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: sarilumab 150 mg + methotrexate
Number of subjects: 1197

Group type: COMPARATOR
Intervention: placebo + methotrexate
Number of subjects: 1197

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: sarilumab 150 mg
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg
Number of subjects: 1197
Study: 30243679

Group type: EXPERIMENTAL
Intervention: Multiple needle puncturing (MNP) using an 18 gauge needle with five punctures each time of release.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Subperiosteal elevation (SE) using a periosteal elevator with an increment depth of 5 mm each time of release.
Number of subjects: 16
Study: 28270164

Group type: EXPERIMENTAL
Intervention: pegcantratinib (TRK inhibitor) applied topically for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo applied topically for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pegcantratinib (TRK inhibitor) applied topically for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pegcantratinib (TRK inhibitor) and placebo
Number of subjects: 20
Study: 25533992

Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF)
Number of subjects: 0
Study: 23806846

Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG and standard luteal phase support (LPS)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa; 0.2 mg triptorelin) and standard LPS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.2 mg triptorelin) and standard LPS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.2 mg triptorelin) without LPS
Number of subjects: 4
Study: 21649843

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist intervention
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 228
Study: 18303466

Group type: EXPERIMENTAL
Intervention: Patients with degenerative lumbar flat back deformity
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 21
Study: 16781361

Group type: EXPERIMENTAL
Intervention: eptifibatide/reduced-dose unfractionated heparin
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: eptifibatide/reduced-dose enoxaparin
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 567
Study: 14700389

Group type: EXPERIMENTAL
Intervention: Listener Comfort Scale (9-point scale)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Speech Naturalness Scale (9-point scale)
Number of subjects: 25
Study: 10634368

Group type: EXPERIMENTAL
Intervention: Spironolactone, flutamide, or finasteride (active drugs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 9198827

Group type: EXPERIMENTAL
Intervention: Nicergoline (8 mg i.v. for 5 days, then 30 mg oral for 25 days)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg i.v. for 5 days, then 800 mg oral for 25 days)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Typical treatment
Number of subjects: 121
Study: 8497681

Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol inhaled 10 min before sBPT (treatment A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol inhaled 2 h before sBPT (treatment B)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo inhalation 10 min before sBPT (treatment A)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo inhalation 2 h before sBPT (treatment B)
Number of subjects: 8
Study: 3518726

Group type: EXPERIMENTAL
Intervention: Ibopamine in association with digitalis and diuretics (10 patients, Group 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Digitalis and diuretics (8 patients, Group 2)
Number of subjects: 18
Study: 29406465

Group type: EXPERIMENTAL
Intervention: Daptomycin (7 mg/kg for 12-17 years, 9 mg/kg for 7-11 years, 12 mg/kg for 1-6 years)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard-of-care (SOC; primarily vancomycin or cefazolin)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 82
Study: 27124034

Group type: EXPERIMENTAL
Intervention: Awake group (LMA removed while following verbal instructions)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Deep group (LMA removed under deep anesthesia with propofol at 2 μg/mL)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study: 25909612

Group type: EXPERIMENTAL
Intervention: Local anesthesia with propofol sedation and pre‐emptive analgesia with ketorolac
Number of subjects: 76

Group type: COMPARATOR
Intervention: Local anesthesia only
Number of subjects: 76
Study: 22276745

Group type: EXPERIMENTAL
Intervention: Immediate salvage therapy (no-ARDFP group)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: ARV drug-free period (ARDFP)
Number of subjects: 283
Study: 19625976

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion at a dosage of 0.3 g.kg(‐1) body weight (BW)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NaCl placebo (PLAC) at a dosage of 0.045 g.kg(‐1) BW
Number of subjects: 10
Study: 19050545

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A combined with other treatment modalities
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A treatment across multiple facial areas
Number of subjects: 23
Study: 15857066

Group type: EXPERIMENTAL
Intervention: ePTFE titanium reinforced membranes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination therapy (bioabsorbable membranes with a bone replacement graft)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bioabsorbable barriers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative
Number of subjects: 40
Study: 12431890

Group type: EXPERIMENTAL
Intervention: Educational outreach intervention (15 practice visits over 21 months)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 124
Study: 10440429

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 19185

Group type: COMPARATOR
Intervention: Aspirin (active control)
Number of subjects: 19185
Study: 8634163

Group type: EXPERIMENTAL
Intervention: Castable glass ceramic crowns (Dicor)
Number of subjects: 101
Study: 2014712

Group type: EXPERIMENTAL
Intervention: 20 mg nicergoline once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4.5 mg co-dergocrine mesilate once daily
Number of subjects: 30
Study: 373642

Group type: EXPERIMENTAL
Intervention: Family psychotherapy (6 hours over 4 months)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 2
Study: 31980515

Group type: EXPERIMENTAL
Intervention: CM-DBS (centromedian thalamic nucleus deep brain stimulation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intraoperative MERs (microelectrode recordings)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Resting-state fMRI connectivity
Number of subjects: 19
Study: 31856887

Group type: EXPERIMENTAL
Intervention: Twice-daily nebulised hypertonic saline (HTS 6%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of twice-daily nebulised HTS and carbocisteine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 28183443

Group type: EXPERIMENTAL
Intervention: Diet rich in n-6PUFA
Number of subjects: 26

Group type: COMPARATOR
Intervention: Diet rich in saturated fatty acids (SFA)
Number of subjects: 26
Study: 25967269

Group type: EXPERIMENTAL
Intervention: Integrated HIV services in ANC clinics
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Nonintegrated PMTCT services
Number of subjects: 1172
Study: 24039715

Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study: 17631079

Group type: EXPERIMENTAL
Intervention: Rhythm control (attempting to maintain sinus rhythm, principally with antiarrhythmic drugs)
Number of subjects: 3032

Group type: COMPARATOR
Intervention: Rate control (allowing AF to persist or recur while controlling the ventricular rate)
Number of subjects: 3032
Study: 14724486

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite cement
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hydroxyapatite granules
Number of subjects: 8
Study: 11057794

Group type: EXPERIMENTAL
Intervention: Meropenem (500 mg) administered intravenously every 12 hrs
Number of subjects: 5
Study: 9493076

Group type: EXPERIMENTAL
Intervention: High-dose growth hormone (GH) treatment, daily s.c. dose of either 0.2 or 0.3 IU/kg for 2 years
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-dose growth hormone (GH) treatment
Number of subjects: 17
Study: 8366456

Group type: EXPERIMENTAL
Intervention: Centric relation mandibular muscle relaxation appliance (MRA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Neuromuscular orthotic
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (cotton rolls)
Number of subjects: 12
Study: 3531567

Group type: EXPERIMENTAL
Intervention: Ceftizoxime suppository (CZX‐S), 250 mg, four times daily for 7 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ceftizoxime intravenous injection (CZX), 60 mg/kg body weight, four times daily for 7 days
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ceftizoxime suppository (CZX‐S)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ceftizoxime intravenous injection (CZX)
Number of subjects: 67
Study: 30926753

Group type: EXPERIMENTAL
Intervention: ebikes
Number of subjects: 14828

Group type: COMPARATOR
Intervention: bicycles
Number of subjects: 14828

Group type: EXPERIMENTAL
Intervention: ebike drivers
Number of subjects: 14828

Group type: EXPERIMENTAL
Intervention: ebike passengers
Number of subjects: 14828

Group type: EXPERIMENTAL
Intervention: commercial ebikes
Number of subjects: 14828

Group type: COMPARATOR
Intervention: ebikes vs bicycles
Number of subjects: 14828

Group type: COMPARATOR
Intervention: males vs females
Number of subjects: 14828

Group type: COMPARATOR
Intervention: clear weather vs cloudy, rainy and snowy
Number of subjects: 14828

Group type: COMPARATOR
Intervention: helmet users vs nonusers
Number of subjects: 14828
Study: 30289435

Group type: EXPERIMENTAL
Intervention: MK-2048 (30 mg) and vicriviroc (VCV, 182 mg) vaginal rings used continuously for 28 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MK-2048 and vicriviroc vaginal rings
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo vaginal rings
Number of subjects: 48
Study: 30022409

Group type: EXPERIMENTAL
Intervention: Patient-family agenda setting intervention (self-administered paper-pencil checklist)
Number of subjects: 93
Study: 26184078

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg melatonin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24193954

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol) 60,000 IU per month for 6 months
Number of subjects: 100
Study: 22348831

Group type: EXPERIMENTAL
Intervention: 0.4% L-menthol (n = 32)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 0.8% L-menthol (n = 35)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 1.6% L-menthol (n = 30)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (n = 34)
Number of subjects: 131